NexMR aims to deliver fully characterized hits to support drug discovery pipelines.
Thanks to our proprietary technology using sensitivity-enhanced NMR we can screen libraries of thousands of molecules within days. We are also able to characterize the hits without idle time, as our technology encompasses affinity and structure determination.
Contrary to state-of-the-art methods (X-ray crystallography, surface plasmon resonance), we only require minimal assay development, allowing us to screen challenging targets which were not addressed so far.
The sample conditions used in NMR are milder and closer to physiological conditions than for other techniques, therefore facilitating the transition to further development.
11.11.2024
Strong startup delegation at Medica 2024 (startupticker.ch)
06.09.2024
Kickfund invests at full throttle (startupticker.ch)
25.01.2024
ZKB Pionierpreis Technopark shortlists 11 startups (startupticker.ch)
23.12.2022
NexMR secures funds to accelerate drug discovery (startupticker.ch)
22.12.2022
NexMR wins CHF 150,000 to develop high throughput screening technique for accelerated drug discovery (venturekick.ch)
No milestones
No Jobs
No videos and documents
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
http://www.vpf.ethz.ch/transfer/firmgruend/spinoff_list/by_years/2009
Website:
www.nexmr.com
Headquarter:
Schlieren
Foundation Date:
May 2022
Technology:
Sectors: